Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 601–700 of 1,000
Genome-Wide Transcription Responses to Synchrotron Microbeam Radiotherapy
Sprung, C. N., Yang, Y., Forrester, H. B., Li, J., Zaitseva, M., Cann, L. M., Restall, T., Anderson, R. L., Crosbie, J. C., & Rogers, P. A. W. (2012) · Radiation Research · doi:10.1667/rr2885.1 · Cited by 46
The Immunoproteasome Cleans up after Inflammation
van Deventer, S. J., & Neefjes, J. (2010) · Cell · doi:10.1016/j.cell.2010.08.002 · Cited by 46
Self-citationLim, J. U., Lee, E., Lee, S., Cho, H. J., Ahn, D. H., Hwang, Y., Choi, J. Y., Yeo, C. D., Park, C. K., & Kim, S. J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-633 · Cited by 45
Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems
Peng, J., Li, S., & Ti, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s457782 · Cited by 45
Radiation and Immune Checkpoint Blockade: From Bench to Clinic
Shabason, J. E., & Minn, A. J. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.03.002 · Cited by 45
Flynn, J. P., O’Hara, M. H., & Gandhi, S. J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.07 · Cited by 45
Schoenhals, J. E., Seyedin, S. N., Anderson, C., Brooks, E. D., Li, Y. R., Younes, A. I. A., Niknam, S., Li, A., Barsoumian, H. B., Cortez, M. A., et al. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.06 · Cited by 45
Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
Li, Y.-Y., Feun, L. G., Thongkum, A., Tu, C.-H., Chen, S.-M., Wangpaichitr, M., Wu, C., Kuo, M. T., & Savaraj, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061297 · Cited by 45
Xu, M. J., Wu, S. Y., DAUD, A. I., Yu, S. S., & Yom, S. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0352-8 · Cited by 45
Spaas, M., & Lievens, Y. N. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00244 · Cited by 45
Hua, Y., You, R., Wang, Z., Huang, P., Lin, M. F., Ouyang, Y., Xie, Y., Zou, X., Liu, Y., Duan, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003290 · Cited by 45
Ye, G. W., Park, J.-B., Park, Y.-J., Choi, Y. S., & Sin, J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300149 · Cited by 45
Abscopal Effects and Yttrium-90 Radioembolization
Ghodadra, A. G., Bhatt, S., Camacho, J. C., & Kim, H. S. (2015) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-015-1259-0 · Cited by 45
Immunotherapy approaches for the treatment of diffuse midline gliomas
Bernstock, J. D., Hoffman, S. E., Kappel, A. D., Valdes, P. A., Essayed, W. I., Klinger, N. V., Kang, K., Totsch, S. K., Olsen, H. E., Schlappi, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124058 · Cited by 44
Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy
Xuan, L., Bai, C., Ju, Z., Luo, J., Guan, H., Zhou, P., & Huang, R. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.003 · Cited by 44
Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy
Shang, Q., Zhang, P., Lei, X., Du, L., & Qu, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530890 · Cited by 44
The Immunology of Ablative Radiation
Burnette, B., & Weichselbaum, R. R. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.009 · Cited by 44
High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma
Mohiuddin, M. M., Park, H., Hallmeyer, S., & Richards, J. M. (2015) · Cureus · doi:10.7759/cureus.417 · Cited by 44
Immunotherapy and radiation therapy for malignant pleural mesothelioma
Alley, E. W., Katz, S. I., Cengel, K. A., & Simone, C. B. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.04.01 · Cited by 44
Tétu, P., Allayous, C., Oriano, B., Dalle, S., Mortier, L., Leccia, M. ‐., Guillot, B., Dalac, S., Dutriaux, C., Lacour, J. ‐., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.009 · Cited by 44
Käsmann, L., Eze, C., Taugner, J., Roengvoraphoj, O., Dantes, M., Schmidt-Hegemann, N.-S., Schiopu, S., Belka, C., & Manapov, F. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01595-3 · Cited by 44
Immunotherapy in prostate cancer: current state and future perspectives
Handa, S., Hans, B., Goel, S., Bashorun, H., Dovey, Z., & Tewari, A. K. (2020) · Therapeutic Advances in Urology · doi:10.1177/1756287220951404 · Cited by 44
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021) · Cancers · doi:10.3390/cancers13061468 · Cited by 45
Emerging Treatment Paradigms in Radiation Oncology
Le, Q., Shirato, H., Giaccia, A. J., & Koong, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1191 · Cited by 44
Chamoto, K., Takeshima, T., Wakita, D., Ohkuri, T., Ashino, S., Omatsu, T., Shirato, H., Kitamura, H., Togashi, Y., & Nishimura, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01114.x · Cited by 44
Hannan, R., Zhang, H., Wallecha, A., Singh, R., Liu, L., Cohen, P., Alfieri, A. A., Rothman, J., & Guha, C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1257-x · Cited by 43
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies
D’Souza, N. M., Fang, P., Logan, J. K., Yang, J., Jiang, W., & Li, J. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00212 · Cited by 44
The anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancer
Walshaw, R. C., Honeychurch, J., Illidge, T., & Choudhury, A. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.172 · Cited by 43
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
Melosky, B. L., Juergens, R. A., Hirsh, V., McLeod, D., Leighl, N. B., Tsao, M., Card, P. B., & Chu, Q. S.-C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0027 · Cited by 43
Alerting the immune system to DNA damage: micronuclei as mediators
MacDonald, K. M., Benguerfi, S., & Harding, S. M. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200016 · Cited by 43
International consensus on radiotherapy in metastatic non-small cell lung cancer
Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., Chen, M., Ma, S., Xie, C., Xu, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-644 · Cited by 43
Kang, K., Wu, Y., Yao, Z., & Lü, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216239 · Cited by 43
de la Cruz‐Merino, L., Lejeune, M., Fernández, E. N., Henao, F., López, A. G., Illescas-Vacas, A., Provencio, M., Callau, C., & Álvaro, T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/756353 · Cited by 43
Fabian, K. P., Kowalczyk, J. T., Reynolds, S. T., & Hodge, J. W. (2022) · Cells · doi:10.3390/cells11233826 · Cited by 43
Self-citationNelde, A., Kowalewski, D. J., Backert, L., Schuster, H., Werner, J.-O., Klein, R., Kohlbacher, O., Kanz, L., Salih, H. R., Rammensee, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316438 · Cited by 42
Suominen, M. I., Wilson, T., Käkönen, S.-M., & Scholz, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163899 · Cited by 42
The Abscopal Effect in the Era of Checkpoint Inhibitors
Kodet, O., Němejcová, K., Strnadová, K., Havlínová, A., Dundr, P., Krajsová, I., Štork, J., Smetana, K., & Lacina, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137204 · Cited by 42
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers
Wong, K. C. W., Johnson, D., Hui, E. P., Lam, R. C. T., Ma, B. B. Y., & Chan, A. T. �. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102361 · Cited by 42
Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction
Ménager, J., Gorin, J., Maurel, C., Drujont, L., Gouard, S., Louvet, C., Chérel, M., Faivre-Chauvet, A., Morgenstern, A., Bruchertseifer, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130249 · Cited by 42
Palayoor, S. T., John‐Aryankalayil, M., Makinde, A. Y., Falduto, M. T., Magnuson, S. R., & Coleman, C. N. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0623 · Cited by 42
Tabi, Z., Spary, L. K., Coleman, S. L., Clayton, A., Mason, M. D., & Staffurth, J. N. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000488 · Cited by 42
Myers, C. J., & Lü, B. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.06.2452 · Cited by 42
Localized Pancreatic Cancer: Multidisciplinary Management
Coveler, A. L., Herman, J. M., Simeone, D. M., & Chiorean, E. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160827 · Cited by 42
He, C., Ding, H.-Y., Li, L., Chen, J., Mo, X., Ding, Y., Chen, W., Tang, Q., & Wang, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s419712 · Cited by 41
Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures
Majumder, A. (2023) · Cancers · doi:10.3390/cancers16010039 · Cited by 41
Progress in the Treatment of Advanced Prostate Cancer
Sternberg, C. N., Petrylak, D. P., Madan, R. A., & Parker, C. C. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.117 · Cited by 42
Rosenzweig, K. E., & Gomez, J. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9678 · Cited by 41
Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?
Kurz, S. C., & Wen, P. Y. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0499-0 · Cited by 41
Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression
Lauber, K., & Dunn, L. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238339 · Cited by 41
Computational modelling of modern cancer immunotherapy
Valentinuzzi, D., & Jeraj, R. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abc3fc · Cited by 41
Reijmen, E., de Mey, S., de Mey, W., Gevaert, T., Ridder, K. D., Locy, H., Martens, S., Blay, E. D., Bouwens, L., Debie, P., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.04.009 · Cited by 41
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients
Balázs, K., Antal, L., Sáfrány, G., & Lumniczky, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040296 · Cited by 41
Silk, A. W., Barker, C. A., Bhatia, S., Bollin, K. B., Chandra, S., Eroglu, Z., Gastman, B., Kendra, K. L., Kluger, H. M., Lipson, E. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004434 · Cited by 41
Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
Rajeev-Kumar, G., & Pitroda, S. P. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100867 · Cited by 41
Chemical biology of antigen presentation by MHC molecules
van Kasteren, S. I., Overkleeft, H. S., Ovaa, H., & Neefjes, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.10.005 · Cited by 41
Self-citationRatikan, J. A., Micewicz, E. D., Xie, M. W., & Schaue, D. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.031 · Cited by 41
Meng, Y., Mauceri, H. J., Khodarev, N. N., Darga, T. E., Pitroda, S. P., Beckett, M. A., Kufe, D. W., & Weichselbaum, R. R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.18 · Cited by 41
Hickey, R., Kulik, L., Nimeiri, H. S., Kalyan, A., Kircher, S. M., Desai, K. R., Riaz, A., Lewandowski, R. J., & Salem, R. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.07.018 · Cited by 41
Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers
Weichselbaum, R. R., & Kufe, D. W. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.37 · Cited by 41
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 42
Ghiringhelli, F., & Rébé, C. (2023) · Immunological Reviews · doi:10.1111/imr.13263 · Cited by 40
Immunotherapy Strategies in the Treatment of Breast Cancer
Soliman, H. H. (2013) · Cancer Control · doi:10.1177/107327481302000104 · Cited by 40
Exploring optimal sequencing of radiation and immunotherapy combinations
Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 40
Jiang, D., Fyles, A., Nguyen, L. T., Neel, B. G., Sacher, A. G., Rottapel, R. K., Wang, B. X., Ohashi, P. S., & Sridhar, S. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26893 · Cited by 40
Rational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 40
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 41
Goedegebuure, R. S. A., Harrasser, M., de Klerk, L. K., Schooten, T. S. G.-V., van Grieken, N. C. T., Eken, M., Grifhorst, M. S., Pocorni, N., Jordanova, E. S., Henegouwen, M. I. V. B., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1954807 · Cited by 40
Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 41
Uchihara, Y., Permata, T. B. M., Sato, H., Kawabata‐Iwakawa, R., Katada, S., Gu, W., Kakoti, S., Yamauchi, M., Kato, R., Gondhowiardjo, S. A., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.030 · Cited by 40
Wiedermann, U., Davis, A. B., & Zielinski, C. C. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2410-8 · Cited by 40
Walshaw, R. C., Honeychurch, J., & Illidge, T. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160472 · Cited by 39
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation
Schrand, B., Verma, B., Levay, A. K., Patel, S., Castro, I., Benaduce, A. P., Brenneman, R., Umland, O., Yagita∥, H., Gilboa, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2105 · Cited by 39
Levey, A. O., Elsayed, M., Lawson, D. H., Ermentrout, R. M., Kudchadkar, R. R., Bercu, Z. L., Yushak, M. L., Newsome, J. M., & Kokabi, N. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02366-8 · Cited by 39
Pierini, S., Mishra, A., Perales-Linares, R. F., Uribe‐Herranz, M., Beghi, S., Giglio, A., Pustylnikov, S., Costabile, F., Rafail, S., Amici, A. R. D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001636 · Cited by 39
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 40
A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors
Huang, K. C., Lai, C.-Y., Hung, W.-Z., Chang, H.-Y., Lin, P.-C., Chiang, S., Ke, T., Liang, J., Shiau, A., Yang, P.-C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0318 · Cited by 39
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies
Solanki, A. A., Bossi, A., Efstathiou, J. A., Lock, D., Mondini, M., Ramapriyan, R., Welsh, J. W., & Kang, J. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.09.013 · Cited by 39
Jiang, J., Li, H.-F., Ma, Q., Liu, J., Ren, F., Song, Y., Wang, T., Li, K., & Li, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1554499 · Cited by 38
Yang, H. J., Jin, T., Li, M., Xue, J., & Lü, B. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz004 · Cited by 38
Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
Movassaghi, M., Chung, R., Anderson, C. B., Stein, M. N., Saenger, Y. M., & Faiena, I. (2021) · Cancers · doi:10.3390/cancers13194757 · Cited by 38
Combining Immunotherapy and Radiation for Prostate Cancer
Finkelstein, S. E., Salenius, S. A., Mantz, C. A., Shore, N. D., Fernández, E. B., Shulman, J., Myslicki, F. A., Agassi, A. M., Rotterman, Y., DeVries, T. A., et al. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.09.001 · Cited by 38
Extrusion of misfolded and aggregated proteins – a protective strategy of aging neurons?
Doehner, J., Genoud, C., Imhof, C., Krstic, D., & Knuesel, I. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08154.x · Cited by 36
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission
Mould, R. C., van Vloten, J. P., AuYeung, A. W. K., Karimi, K., & Bridle, B. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0316 · Cited by 38
Yuan, C., & Wang, Q. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1851-2 · Cited by 38
Fighting cancers from within: augmenting tumor immunity with cytokine therapy
Pellegrini, M., Mak, T. W., & Ohashi, P. S. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.003 · Cited by 39
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine
Riley, J. M., Cross, A. W., Paulos, C. M., Rubinstein, M. P., Wrangle, J. M., & Camp, E. R. (2018) · Cancer · doi:10.1002/cncr.31214 · Cited by 37
Zhou, P., Chen, D., Zhu, B., Chen, W., Xie, Q., Wang, Y., Tan, Q., Yuan, B., Zuo, X., Huang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594212 · Cited by 37
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Turchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0145 · Cited by 37
Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L. J., Green, M. D., & Speers, C. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022542 · Cited by 37
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 38
Corso, C. D., & Bindra, R. S. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.06.003 · Cited by 37
Sun, Y., Zheng, Z., Zhang, H., Yu, Y., Ma, J., Tang, K., Xu, P., Ji, T., Liang, X., Chen, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1309487 · Cited by 36
The Role of Radiation Oncology in Immuno-Oncology
Meng, X., Feng, R., Yang, L., Xing, L., & Yu, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s04 · Cited by 36
Chu, C., Chiu, T.-H., Wang, C., Chang, W., Huang, A. C., Liu, C., Wang, C., Ko, H., Chung, F., Hsu, P., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13426 · Cited by 36
Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity
Tuomela, K., Mukherjee, D., Ambrose, A. R., Harikrishnan, A., Mole, H., Hurlstone, A. F. L., Önfelt, B., Honeychurch, J., & Davis, D. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111900119 · Cited by 36
Exploiting radiation immunostimulatory effects to improve glioblastoma outcome
Awada, H., Paris, F., & Pecqueur, C. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac239 · Cited by 36
Sato, H., Suzuki, Y., Ide, M., Katoh, T., Noda, S., Ando, K., Oike, T., Yoshimoto, Y., Okonogi, N., Mimura, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108122 · Cited by 36
Demaria, S., Vanpouille‐Box, C., Formenti, S. C., & Adams, S. (2013) · OncoImmunology · doi:10.4161/onci.25997 · Cited by 36
Spontaneous regression of natural killer cell lymphoma
Isobe, Y., Aritaka, N., Sasaki, M., Oshimi, K., & Sugimoto, K. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.062976 · Cited by 36
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.